Back to search

Article

TREM2 Activation by First-in-Class Direct Small Molecule Agonists: DEL Screening, Optimization, Biophysical Validation, and Functional Characterization

2025-05-27

Abstract excerpt

<h4>ABSTRACT</h4> Triggering receptor expressed on myeloid cells 2 (TREM2) is a key regulator of microglial function, and its loss-of-function variants are linked to Alzheimer’s disease (AD) and neurodegenerative disorders. While TREM2 activation is a promising therapeutic strategy, no small molecule agonists acting via direct TREM2 binding have been reported to date. Here, we describe the discovery of first-in-c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f42a3b1e-e6ff-563c-a786-32b98724f513
DOI
10.1101/2025.05.22.655617
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
TREM2 Activation by First-in-Class Direct Small Molecule Agonists: DEL Screening, Optimization, Biophysical Validation, and Functional CharacterizationDOI 10.1101/2025.05.22.655617
Select a neighboring publication to make it the new centre.